BioMimetic Therapeutics, Inc.
) recently announced that it has started enrolling patients for a
phase II trial of its candidate, Augment Chronic Tendinopathy
(ACT) for the treatment of lateral epicondylitis (tennis elbow).
ACT is based on recombinant human platelet-derived growth factor.
The company expects to complete the enrollment process by the end
of this year.
AMGEN INC (AMGN): Free Stock Analysis Report
BIOMIMETIC THER (BMTI): Free Stock Analysis
REPLIGEN (RGEN): Free Stock Analysis Report
TARGACEPT INC (TRGT): Free Stock Analysis
To read this article on Zacks.com click here.
The company intends to enroll up to 100 patients in this
randomized, escalating dose, double-blinded, placebo controlled
and multi-center phase II trial. The trial will evaluate the
safety and efficacy profile of ACT ascending doses. In the trial
patients, aged between 21 and 80 years will receive one injection
of either placebo or any of the four different doses of ACT into
the extensor carpi radialis brevis (ECRB).
The efficacy of the candidate will be measured on the basis of
visual analog scale (VAS), disabilities of the arm, shoulder and
hand (DASH) score and the patient rated tennis elbow evaluation
(PRTEE) and grip strength testing.
In November 2012, BioMimetic entered into an agreement with
Wright Medical Group, Inc. to combine both the businesses. We
believe that the BioMimetic's biologics pipeline will complement
Wright's product portfolio. The deal is expected to close in the
first quarter of 2013, subject to approval by BioMimetic
We currently have a Neutral recommendation on Biomimetic
Therapeutics Inc. The stock carries a Zacks #1 Rank (Strong Buy)
in the short run.
Other Zacks #1 Rank stocks include